Nicox Announces Presentations at the Upcoming ARVO Annual Meeting 2024

Nicox SA announced presentations on NCX 470 and NCX 1728 at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 5-9, 2024 in Seattle.

Abstract/Presentation Title: Tolerability and intraocular pressure (IOP)-lowering efficacy following 5-day repeated dosing with NCX 470 0.1% ophthalmic solution, Lumigan and Rhopressa: a comparative head-to-head study in rabbits and dogs 
Type: Poster Session 
Session Title: Tools and advancements in glaucoma diagnosis, monitoring, medications, and lasers 
Date: May 6, 2024 from 8:30 am to 10:15 am (U.S. local time)
Presenter: Francesco Impagnatiello, PhD, Nicox Research Institute

NCX 470, a novel NO-donating bimatoprost eye drop, is currently in phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the two phase 3 clinical trials, have been announced in October 2022. The second phase 3 clinical trial, Denali, is currently ongoing, and the results are expected in 2025, based on current recruitment rates.

Abstract/Presentation Title: NCX 1728, a novel nitric oxide (NO)-donating avanafil: Formulation development and in vivo testing in a rabbit model of ischemia/reperfusion injury of the optic nerve head and retina 
Type: Poster Session 
Session Title: Neuroprotection, blood flow, ischemia-reperfusion and aqueous humor dynamics 
Date: May 5, 2024 from 3:15 pm to 5:00 pm (U.S. local time) 
Presenter: Corinna Galli, PhD, Nicox Research Institute

NCX 1728 is an NO-donating phosphodiesterase-5 (PDE5) inhibitor, the lead compound in a new class of NO-donating molecules based entirely on NO-mediated activity. NCX 1728 is currently under preclinical evaluation for development in retinal conditions.

Nicox Corporate Status Update

Nicox estimates it is financed until June 2024, based exclusively on the development of NCX 470. The company is pursuing licensing and other business development discussions, exploring multiple strategic options and is also discussing with its creditors to restructure its debt.